Eduardo Anitua

Dr. Eduardo Anitua

BTI Biotechnology Institute, University Institute for Regenerative Medicine and Oral Implantology—UIRMI (UPV/EHU-Fundación Eduardo Anitua), Vitoria, Spain
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
EAEduardo Anitua
Eduardo Anitua
IAIsabel Andia
Isabel Andia
BABruno Ardanza
Bruno Ardanza
PNPaquita Nurden
Paquita Nurden
ANAlan Nurden
Alan Nurden
Summary: Platelets are known for their role in haemostasis where they help prevent blood loss at sites of vascular injury. To do this, they adhere, aggregate and form a procoagulant surface leading to thrombin generation and fibrin formation. Platelets also release substances that promote tissue repair and influence the reactivity of vascular and other blood cells in angiogenesis and inflammation. They contain storage pools of growth factors including PDGF, TGF-β and VEGF as well as cytokines including proteins such as PF4 and CD40L. Chemokines and newly synthesised active metabolites are also released. The fact that platelets secrete growth factors and active metabolites means that their applied use can have a positive influence in clinical situations requiring rapid healing and tissue regeneration. Their administration in fibrin clot or fibrin glue provides an adhesive support that can confine secretion to a chosen site. Additionally, the presentation of growth factors attached to platelets and/or fibrin may result in enhanced activity over recombinant proteins. Dental implant surgery with guided bone regeneration is one situation where an autologous platelet-rich clot clearly accelerates ossification after tooth extraction and/or around titanium implants. The end result is both marked reductions in the time required for implant stabilisation and an improved success rate. Orthopaedic surgery, muscle and/or tendon repair, reversal of skin ulcers, hole repair in eye surgery and cosmetic surgery are other situations where autologous platelets accelerate healing. Our aim is to review these advances and discuss the ways in which platelets may provide such unexpected beneficial therapeutic effects.

1 February 2007 in The American Journal of Sports Medicine
Verified
Journal Article
Closed access
MSMikel Sánchez
Mikel Sánchez
EAEduardo Anitua
Eduardo Anitua
JAJuan Azofra
Juan Azofra
IAIsabel Andia
Isabel Andia
SPSabino Padilla
Sabino Padilla
IMIñigo Mujika
Iñigo Mujika
Background: Platelet-rich fibrin matrices release a natural mixture of growth factors that play central roles in the complex processes of tendon healing. Hypothesis: Application of autologous platelet-rich matrices during Achilles tendon surgery may promote healing and functional recovery. Study Design: Case-control study and descriptive laboratory study; Level of evidence, 3. Methods: Twelve athletes underwent open suture repair after complete Achilles tendon tear. Open suture repair in conjunction with a preparation rich in growth factors (PRGF) was performed in 6 athletes and retrospectively compared with a matched group that followed conventional surgical procedure. The outcomes were evaluated on the basis of range of motion, functional recovery, and complications. Achilles tendons were examined by ultrasound at 50 ± 11 months in retrospective controls and 32 ± 10 months in the PRGF group. In the laboratory portion of the study, PRGF treatment was characterized by the number of platelets and concentration of insulin (IGF-I), transformed (TGF-β1), platelet-derived (PDGF-AB), vascular endothelial (VEGF), hepatocyte (HGF), and epidermal (EGF) growth factors in patients affected by musculoskeletal traumatic injuries. Results: Athletes receiving PRGF recovered their range of motion earlier (7 ± 2 weeks vs 11 ± 3 weeks, P = .025), showed no wound complication, and took less time to take up gentle running (11 ± 1 weeks vs 18 ± 3 weeks, P = .042) and to resume training activities (14 ± 0.8 weeks vs 21 ± 3 weeks, P = .004). The cross-sectional area of the PRGF-treated tendons increased less (t = 3.44, P = .009). TGF-β1 (74.99 ± 32.84 ng/mL), PDGF-AB (35.62 ± 14.57 ng/mL), VEGF (383.9 ± 374.9 pg/mL), EGF (481.5 ± 187.5 pg/mL), and HGF (593.87 ± 155.76 pg/mL) significantly correlated with the number of platelets (677 ± 217 platelets/μL, P < .05). Conclusion: The operative management of tendons combined with the application of autologous PRGF may present new possibilities for enhanced healing and functional recovery. This needs to be evaluated in a randomized clinical trial.

1 November 2007 in Biomaterials
Verified
Journal Article
Closed access
EAEduardo Anitua
Eduardo Anitua
MSMikel Sánchez
Mikel Sánchez
GOGorka Orive
Gorka Orive
IAIsabel Andia
Isabel Andia

1 May 2006 in Trends in Biotechnology
Verified
Journal Article
Closed access
EAEduardo Anitua
Eduardo Anitua
MSMikel Sánchez
Mikel Sánchez
ANAlan T. Nurden
Alan T. Nurden
PNPaquita Nurden
Paquita Nurden
GOGorka Orive
Gorka Orive
IAIsabel Andia
Isabel Andia

1 March 2005 in Journal of Orthopaedic Research
Verified
Journal Article
Closed access
EAEduardo Anitua
Eduardo Anitua
IAIsabel Andia
Isabel Andia
MSMikel Sanchez
Mikel Sanchez
JAJuan Azofra
Juan Azofra
MZMa del Mar Zalduendo
Ma del Mar Zalduendo
ANAlan T. Nurden
Alan T. Nurden

5 August 2009 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
GOGorka Orive
Gorka Orive
EAEduardo Anitua
Eduardo Anitua
José Luis PedrazJosé Luis Pedraz
José Luis Pedraz
DEDwaine F. Emerich
Dwaine F. Emerich